1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SRSF2-P95H delays myelofibrosis development through altered JAK/STAT signaling in JAK2(V617F) megakaryocytes
    Meeting Abstract

    Willekens, C.; Laplane, L.; Dagher, T.; Benlabiod, C.; Lacout, C.; Rameau, P.; Catelain, C.; Alfaro, A.; Edmond, V.; Signolle, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of extended use of romiplostim treatment for chemotherapy-induced thrombocytopenia
    Meeting Abstract

    Wilkins, C. R.; Ortiz, J.; Gilbert, L.; Yin, S.; Mones, J. V.; Parameswaran, R.; Mantha, S.; Soff, G. A.
    Blood (2021)

    Fulltext@MSK | Save
  • Disease-modifying potential of bet inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis - preliminary Data
    Meeting Abstract

    Verstovsek, S.; Salama, M. E.; Mascarenhas, J.; Talpaz, M.; Mesa, R. A.; Vannucchi, A.; Rampal, R.; Oh, S. T.; Olteanu, H.; Chiu, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K.; Fenske, T. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Modulation of RNA splicing enhances response to BCL2 inhibition in acute myeloid leukemia
    Meeting Abstract

    Wang, E.; Pineda, J. M. B.; Bourcier, J.; Stahl, M.; Penson, A. V.; Wakiro, I.; Singer, M. E.; Cui, D.; Erickson, C.; Knorr, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • ERK2 substrate binding domains perform opposing roles in pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm
    Meeting Abstract

    Truong, B.; Zhang, Y.; Fahl, S.; Qcai, K.; Martinez, E.; Al-Saleem, E.; Gong, Y.; Liebermann, D.; Soboloff, J.; Dunbrack, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Real-world management of patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens: Results from the AML Real World Evidence (ARC) Initiative
    Meeting Abstract

    Vachhani, P.; Wolach, O.; Garcia, J. S.; Zeidner, J. F.; Talati, C.; Pollyea, D. A.; Lai, C.; Moshe, Y.; Abedin, S.; Lavie, D.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Pharmacodynamic analysis of CAR-T cell persistence in patients with hematologic malignancies treated with NKTR-255, an IL-15 receptor agonist that enhances CD8 (+) T-cells: Preliminary results from a phase 1 study
    Meeting Abstract

    Turtle, C. J.; Budde, E.; Patel, K. K.; Perales, M. A.; Cowan, A. J.; Saeed, H.; Chavez, J. C.; Hirayama, A. V.; Kirchmeier, D. R.; Janakiram, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study
    Meeting Abstract

    Trudel, S.; Cohen, A. D.; Krishnan, A. Y.; Fonseca, R.; Spencer, A.; Berdeja, J. G.; Lesokhin, A.; Forsberg, P. A.; Laubach, J. P.; Costa, L. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Gilteritinib (GILT) monotherapy with addition of decitabine (DEC) in non-responders in older newly diagnosed (ND) FLT3 mutated acute myeloid leukemia (AML) patients having high and low variant allele frequency (VAF): A phase 2/1b sub-study of the Beat AML Master Trial
    Meeting Abstract

    Traer, E.; Huang, Y.; Mims, A. S.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
    Blood (2021)

    Fulltext@MSK | Save